Navigation Links
Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
Date:5/9/2008

TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a centrally acting oral analgesic, provided significant relief for patients with joint-disease pain, compared to those treated with placebo, and with fewer gastrointestinal side effects than those treated with an older, prescription pain reliever, researchers announced today.

Results from a Phase 3 clinical study of tapentadol immediate release (IR) tablets showed that patients treated with a 50 mg or 75 mg dose of tapentadol experienced significant relief in end-stage joint disease pain compared to placebo (P<0.001) when assessed over five days of treatment. In addition, patients treated with tapentadol experienced significantly better digestive tract tolerability compared to patients treated with 10 mg of oxycodone IR. Digestive tract tolerability is one of the leading causes of treatment discontinuation for patients who take prescription pain medications.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) presented these new data in a poster session at the 27th Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.

Tapentadol has a unique profile with two mechanisms of action, combining mu-opioid receptor agonism and norepinephrine reuptake inhibition in a single molecule. It is being developed in immediate-release formulation for acute pain and extended-release formulation for chronic pain.

Mu-opioid agonists are drugs that bind to and activate mu-opioid receptors in the central nervous system. These drugs modify sensory and affective (mood) aspects of pain, inhibit the transmission of pain at the spinal cord and affect activity at parts of the brain that control how pain is perceived. Nor
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... 2014  Diplomat, the nation,s largest independent specialty pharmacy, ... to the Board of Directors on September 15, 2014. ... serve as chair of the Audit Committee. ... financial, compliance and operating experience in the health care ... chief financial officer, chief operating officer and secretary of ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... SPRING, Md., March 30 The Laboratory Response Network ... public in health emergencies, will mark its first decade ... 2009.Founded in 1999 by the Association of Public Health ... (CDC) and the Federal Bureau of Investigation (FBI) to ...
... 29 Results from a new sub-,analysis of ... to normal,cholesterol levels and elevated high sensitivity C-reactive ... LDL-C <70mg/dL and hsCRP <2mg/L with,CRESTOR(R) (rosuvastatin calcium) ... to placebo than those who did not (65% ...
Cached Medicine Technology:Nation's Laboratory Response Network Marks First Decade of Protecting Public Health 2CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis 2CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis 3CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis 4
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... patients burdened by stress and family conflicts before surgery ... operation, a new study suggests. Investigators found that ... a nearly three times greater risk for complications compared ... life. "We,ve long known that patient quality of ...
(Date:9/19/2014)... using intact cells to treat and cure disease ... it is hindered by the inability of doctors and ... of these cells in patients without resorting to invasive ... September 17 in the online journal Magnetic Resonance ... San Diego School of Medicine, University of Pittsburgh and ...
(Date:9/19/2014)... --- Domestic violence occurs at least as frequently, ... compared to opposite-sex couples, according to a review ... , Previous studies, when analyzed together, indicate that ... of lesbian, gay and bisexual individuals. However, a ... paints an incomplete picture of the true landscape, ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... M.D., a second-year resident in the Department of ... Medicine and Health Sciences, received at $154K grant ... presence of diffuse brain swelling and injury in ... epidemiological studies, intracerebral hemorrhage accounts for less than ... least treatable form of stroke, with the highest ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Domestic violence likely more frequent for same-sex couples 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2
... use of designated drivers and open dialogue between parents ... ... Attorney General Bob,McDonnell today launched a campaign aimed at preventing drunk driving ... on stations throughout the state. The spots are timed to,coincide with the ...
... Third ... Straight Year, FLINT, Mich., Oct. 26 ... Medicaid health,plans have been recognized by U.S. News & World Report as ... top 50,Commercial plans and the top 25 plans for both Medicare and ...
... website allows consumers to share experiences on anti-aging and ... ... ( http://www.realself.com ),today announced the public launch of the first consumer ... lifestyle choices. On RealSelf.com, consumers engage in an,open and honest conversation ...
... Help End Insurance Coverage Exclusions for,Pre-existing Conditions for ... The National Patient,Advocate Foundation (NPAF) -- a ... avenues of improved patient access to health,care through ... levels -- today,praised Senator Jay Rockefeller (D-WV) for ...
... 26 Uroplasty, Inc. (Amex:,UPI) announced today that ... of fiscal 2008 ended September 30, 2007, before ... Company will host a conference call to,discuss these ... a.m. Central,Time. David Kaysen, President and Chief Executive ...
... YORK, Oct. 26 American Oriental,Bioengineering, Inc. (NYSE: ... of,plant-based pharmaceutical and nutraceutical products in China, today,announced ... in,November. The Company will present at the ... November 6, 2007 at the Waldorf-Astoria,Hotel in New ...
Cached Medicine News:Health News:Virginia Attorney General Addresses Drunk Driving and Underage Drinking in New Radio Campaign 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 3Health News:National Patient Advocate Foundation Hails Senator Rockefeller for Introducing Bill Protecting Patient Access to Health Coverage 2Health News:American Oriental Bioengineering Announces Participation in November Healthcare Conferences 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
Medicine Products: